A local medical company has secured more international distribution deals.
Rampart IC, a Birmingham-based medical device company specializing in radiation shielding and produced the Rampart M1128 device, has signed four separate agreements that have secured the company’s distribution throughout most European countries and in some Middle Eastern nations.
The company has also achieved the CE marking, indication that the product has been assessed by the manufacturer and is deemed to meet European Union safety, health and environmental protection requirements. According to Rampart IC, this marking is required for all commercial products to be marketed in the EU.
“We appreciate our international partners who are facilitating global adoption of Rampart, as it’s a solution for a universal problem,” said Tom Livingston, CEO of Rampart IC. "Dr. Bob Foster’s mission to create a safer cath lab experience for himself and his colleagues in Alabama will benefit future generations of ICs worldwide, who will not have to endure the injuries associated with heavy lead aprons. Our partners share our vision and mission to facilitate quality care for patients without compromising the health and safety of ICs.”
The company has secured distribution through several partners. This includes Sweden-based EPS Vascular, which will distribute the product throughout most European nations including Norway, Sweden, Finland, Iceland, Denmark, Estonia, Latvia, Lithuania, The Netherlands, Belgium, Luxembourg, Germany, Ireland, Czech Republic, Slovakia, Poland, Turkey, Romania, Hungary, Slovenia, Croatia, Serbia, North Macedonia and Bosnia and Herzegovina.
“EPS Vascular and our wider interventional group across Europe, who form part of the SISK Healthcare Group, are excited to partner with Rampart IC to bring their game-changing radiation protection into the Nordic, former Eastern Europe, Ireland, Germany and Benelux markets,” said Joakim Erikson, CEO of EPS Healthcare. “EPS sees a great need to protect our interventional customers and their teams from the occupational injuries that are prevalent in this space globally and we are committed to providing a solution that both offers superior radiation protection as well as protection against orthopedic injury.”
United Kingdom-based Vascular Perspectives will distribute throughout England, Wales and Scotland. Rome-based Bioquantek will distribute throughout Italy, San Marino and Vatican City. Bahrain-based Gulf House Medical Systems will distribute Rampart’s product in Bahrain and Eastern Saudi Arabia.
International distribution has been a major focus for the company as leaders secured the first international distribution agreement with Wilhelm Integrated Solutions, enabling distribution for Australia and New Zealand. The M1128 was developed for interventional cardiologists (ICs) but has found its way into several interventional specialties.
The company’s product is already in used in several health care systems in the U.S. including Ascension, Sutter Health, Northwell, UAB Medicine and Emory University Healthcare System.
“The successful introduction of Rampart will allow health care professional to continue to deliver lifesaving treatments to patients without incurring the risks of chronic exposure to ionizing radiation,” said James Spratt, professor and interventional cardiologist at St Georges, University of London. “This should allow further development of percutaneous treatments and prolong the careers of HCPs working within the field.”
